Back

Neprilysin inhibition reduces microtubule detyrosination in cardiomyocytes through a cGMP-PRKG1-VASH1 axis

Meyer-Jens, M.; Sanyal, C.; Pietsch, N.; Ramirez-Rios, S.; Herrera-Rivero, M.; Kraemer, E.; Braren, I.; Nikolaev, V.; Frye, M.; Koenemann, S.; Schlossarek, S.; Moutin, M.-J.; Carrier, L.

2026-03-16 cell biology
10.64898/2026.03.13.711248 bioRxiv
Show abstract

Microtubule detyrosination and re-tyrosination on the C-terminus of -tubulin are mediated by the vasohibin (VASH)-small vasohibin-binding protein (SVBP) complex and tubulin tyrosine ligase (TTL), respectively. Elevated levels of detyrosinated -tubulin (dTyr-tub) are observed in heart failure, and reducing this modification improves cardiac function, suggesting that clinically used heart failure therapies may modulate microtubule detyrosination. We investigated whether sacubitrilat and valsartan, the active components of the angiotensin receptor-neprilysin inhibitor LCZ696, influence dTyr-tub levels in endothelin-1 (ET1)-induced hypertrophy in human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs). While both sacubitrilat and valsartan prevented hypertrophy, only sacubitrilat prevented ET1-induced dTyr-tub accumulation. RNA sequencing revealed that sacubitrilat normalized several ET1-induced dysregulated pathways. Sacubitrilat slightly increased cyclic guanosine 3,5-monophosphate (cGMP) levels and lowered dTyr-tub, whereas inhibition or knockdown of the cGMP-dependent protein kinase 1 (PRKG1) increased dTyr-tub level. Mechanistically, PRKG1 alpha phosphorylated native VASH1. Incubation of microtubules with the VASH1-SVBP complex containing wild-type VASH1 increased detyrosination, while incubation of the complex containing a VASH1 phosphomimic, in which seven C-terminal serine residues were mutated to glutamate (VASH1-7E) did not. Consistently, overexpression of VASH1-7E gave rise to lower dTyr-tub level than overexpression of a non-phosphorylatable form of VASH1 (VASH1-7A) in hiPSC-CMs deficient in VASH1. In conclusion, these findings identify a cGMP-PRKG1-VASH1 signaling axis that reduces microtubule detyrosination in cardiomyocytes. Our work provides mechanistic insight into how neprilysin inhibition may contribute to therapeutic benefit in heart failure. One Sentence SummaryWe establish a neprilysin-cGMP-PRKG1-VASH1 signaling axis that reduces microtubule detyrosination in cardiomyocytes.

Matching journals

The top 5 journals account for 50% of the predicted probability mass.

1
Journal of Molecular and Cellular Cardiology
39 papers in training set
Top 0.1%
28.8%
2
Circulation Research
39 papers in training set
Top 0.1%
8.7%
3
Circulation
66 papers in training set
Top 0.5%
7.5%
4
JCI Insight
241 papers in training set
Top 0.6%
5.0%
5
Journal of the American Heart Association
119 papers in training set
Top 1%
5.0%
50% of probability mass above
6
eLife
5422 papers in training set
Top 24%
3.7%
7
Circulation: Heart Failure
14 papers in training set
Top 0.2%
3.2%
8
Frontiers in Cardiovascular Medicine
49 papers in training set
Top 1%
2.8%
9
JACC: Basic to Translational Science
15 papers in training set
Top 0.1%
2.5%
10
Cardiovascular Research
33 papers in training set
Top 0.3%
2.2%
11
Scientific Reports
3102 papers in training set
Top 52%
2.0%
12
American Journal of Physiology-Heart and Circulatory Physiology
32 papers in training set
Top 0.6%
1.8%
13
iScience
1063 papers in training set
Top 13%
1.8%
14
European Heart Journal
16 papers in training set
Top 0.4%
1.7%
15
Journal of the American Society of Nephrology
52 papers in training set
Top 0.4%
1.7%
16
PLOS ONE
4510 papers in training set
Top 59%
1.3%
17
Cells
232 papers in training set
Top 5%
0.9%
18
Frontiers in Physiology
93 papers in training set
Top 5%
0.8%
19
PLOS Genetics
756 papers in training set
Top 14%
0.8%
20
Stem Cell Reports
118 papers in training set
Top 0.9%
0.8%
21
Cell Reports Medicine
140 papers in training set
Top 7%
0.8%
22
Frontiers in Cell and Developmental Biology
218 papers in training set
Top 9%
0.7%
23
Physiological Reports
35 papers in training set
Top 1%
0.7%
24
Frontiers in Pharmacology
100 papers in training set
Top 5%
0.7%
25
Nature Cardiovascular Research
28 papers in training set
Top 0.7%
0.5%
26
American Journal of Physiology-Cell Physiology
34 papers in training set
Top 0.5%
0.5%
27
The Journal of Physiology
134 papers in training set
Top 2%
0.5%
28
Hypertension
32 papers in training set
Top 0.9%
0.5%